Tempus’ Patient-Derived Organoid Screens

Fixed panels:

• PanCancer: ~50 PDOs across 10 indications to support testing across small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and more.
• PanCancer IO: ~50 PDOs across 10 indications optimized for evaluating immuno-oncology (IO) agents, including cell therapies, bi-specific T-cell engagers (BITEs), and immune checkpoint inhibitors (ICIs).
• PanCRC: 40 colorectal cancer (CRC) PDOs enriched for pre-treated models,  suitable for assets intended as 2L/3L therapies.

Key insights:

• Viability assessments via luminescence and/or fluorescence readouts
• Responses to standard of care (SOC) therapies
• Molecular characterization of each organoid at baseline with Tempus xT & xR NGS assays (648 genes, full transcriptome)
• Bioinformatics analyses to help inform molecular drivers of response or resistance

Seamlessly synergize biomarkers uncovered with Tempus Explore. 
Our expert data scientists and computational biologists leverage our vast real-world data (RWD) library to generate and help validate hypotheses across 1,000,000+ records with matched de-identified clinical data linked with genomic information.

Enrollment is open through June 30, 2025. Space is limited – complete the form now to secure your spot.